The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781
Authors:
- Katherine BungeKBKatherine Bunge
- Ingrid MacioIMIngrid Macio
- Leslie MeynLMLeslie Meyn
- Lisa NoguchiLNLisa Noguchi
- Michael A. ParniakMPMichael A. Parniak
- Jill L. SchwartzJSJill L. Schwartz
- Bernard MonclaBMBernard Moncla
- Sharon HillierSHSharon Hillier
- 1 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 60 (4) , 337-343
Abstract
: To evaluate the persistence and acceptability of a minimally absorbed vaginal gel antiretroviral designed to block the acquisition of HIV. : Sixty healthy women aged 18-45 participated in a phase-1 randomized placebo-controlled trial of a vaginal gel containing the nonnucleoside reverse transcriptase inhibitor UC781. Women underwent a single timed exposure ranging from 0 to 8 hours and were followed for 35 days. Safety was assessed by symptoms, physical exam, laboratory evaluation, and colposcopy. Persistence was assessed by drug levels in cervicovaginal lavage (CVL) and vaginal swab specimens. : The participants' mean age was 26 years; 77% were white. The most frequently reported adverse events were genitourinary; however, the placebo and UC781 arms had a similar distribution of mild and moderate genitourinary events. All colposcopic findings were superficial. Measuring systemic UC781 levels in the plasma revealed that 2 (5%) women in the UC781 gel group had detectable UC781; however, the amount was below the limits of quantification (2.5 ng/mL) in both participants. UC781 was detected in 37 of 40 CVL samples obtained 1-2 days after drug exposure and initial CVL; the median level of UC781 was 4965 pmol/mL, significantly higher than the known IC50 of 10 pmol/mL. Eighty percent of participants reported that they would use the product if it were found to be protective against HIV. : In this population of HIV-uninfected women, the gel was well tolerated and acceptable. Active levels of drug were detected in CVL and vaginal swab specimens at 1-2 days at concentrations supporting the role for daily dosing.Keywords
This publication has 22 references indexed in Scilit:
- First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo EfficacyPLOS ONE, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical TrialsPLOS ONE, 2010
- Reverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesAntimicrobial Agents and Chemotherapy, 2009
- SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in NigeriaPLOS ONE, 2008
- SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in GhanaPLOS ONE, 2007
- Preclinical Safety Assessments of UC781 Anti-Human Immunodeficiency Virus Topical Microbicide FormulationsAntimicrobial Agents and Chemotherapy, 2007
- Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicidesAIDS, 2006
- Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety studyAIDS, 2006
- The Thiocarboxanilide Nonnucleoside UC781 Is a Tight-Binding Inhibitor of HIV-1 Reverse TranscriptaseBiochemistry, 1997